On November 12, Quantinuum fell 5.01% in Regular Trading, trading at $40.85 per share with turnover of $77.56 million.
The latest catalyst in public news flow was a fresh round of post-earnings target-price cuts from brokers, which appeared to pressure sentiment despite maintained positive ratings.
After its November 5 quarterly release, Quantinuum reported third-quarter revenue of $9.1 million, above consensus near $8.1 million, and raised full-year revenue guidance to $31 million-$34 million from $28 million-$32 million. However, analysts lowered valuation targets afterward, including UBS cutting its target to $50 from $93 while keeping a buy rating; other firms also reduced targets to levels such as $70, $60, and $65. The combination suggests the market is reassessing valuation and commercialization timing even as revenue trends improved.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments